ESH Video


July 25, 2023


7th Translational Research Conference



October 20-22, 2023

Estoril, Portugal





Welcome to the confirmed speakers of #ESHLYMPHOID2023:


Stefan ALIG (Stanford) Georg LENZ (Muenster)
Ash ALIZADEH (Stanford) Ari MELNICK (New York)
Silvia BEA (Barcelona) David MIKLOS (Stanford)
Catherine BOLLARD (Washington) Teresa PALOMERO (New York)
Riccardo DALLA-FAVERA (New York) Mark ROSCHEWSKI (Bethesda)
Alexey DANILOV (Los Angeles) Gilles SALLES (New York)
Silvia DEAGLIO (Turin) David SCOTT (Vancouver)
Moritz FÜRSTENAU (Cologne) Laurie SEHN (Vancouver)
Paolo GHIA (Milan) Margaret SHIPP (Boston)
Michael HALLEK (Cologne) Louis STAUDT (Bethesda)
Daniel HODSON (Cambridge) Karin TARTE (Rennes)
Martin HUTCHINGS (Copenhagen) Jason WESTIN (Houston)
Javeed IQBAL (Omaha) Wyndham WILSON (Bethesda)
Daniel KRAPPMANN (Neuherberg) Catherine WU (Boston)


Register now & join them in Estoril, Portugal!





About the Conference:

ESH Translational Research Conferences focus on leading-edge basic, clinical and therapeutic research and future perspectives.
The presentation of unpublished data is encouraged.

This leading-edge translational research conference will address the rapidly evolving field of lymphoid malignancies, including T- and B-cell lymphomas, and chronic lymphocytic leukaemia (CLL), from molecular pathogenesis to state-of-the-art treatment and future perspectives.
The goals of this conference are to:
- foster scientific exchange between laboratory scientists and clinicians working on lymphoid malignancies worldwide.
- foster scientific cross-fertilization between researchers and clinicians working on different diseases with partially overlapping pathogenic mechanisms such as the B cell receptor signaling, alterations of the DNA damage response, or the increasingly important dialogue of lymphoid tumour cells with their microenvironment.
- provide opportunities for leading-edge education and international networking to basic and clinical scientists, including those still in-training

A first-class selection of international speakers will guarantee the highest quality of science and a summary of the most recent developments in the biology and therapy of Lymphoid Malignancies.




- Biology of diffuse large B cell lymphoma subtypes II
- Novel molecular lymphoma subtypes
- Epigenetic and genetic regulation of clonal lymphoma evolution
- Lymphoma cell interactions in the tumor microenvironment
- Monoclonal antibodies & non-cellular immune therapies
- Cellular immune therapies
- Small molecular pathway inhibitors
- Combination therapies
- Use of CT DNA for diagnostic and therapeutic monitoring



- Current developments in the field of molecular pathogenesis of indolent
and aggressive B-cell lymphoma including CLL
- Current developments in the field of the molecular pathogenesis of T-cell lymphoma
- Prognostic and predictive markers and their impact in specific clinical situations


The programme will include:

Plenary Sessions - Simultaneous Meet the Experts Sessions
Round Table Discussions - Brief Oral Communications
Mentored Poster Walk - Ample time for in-depth discussion



For more information, click here!



With the support of*:

Premium Conference Partner

*ESH conference programmes are developed in strict scientific independence
with no input from corporate sponsors.